Replies to post #249432 on Biotech Values

[Mufaso]

EXAS-MYNZ - The data for MYNZ ColoAlert is similar to what EXAS got in their BLUE-C Study for their next gen Cologuard test.

https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2023/Next-generation-Cologuard-Test-Demonstrates-94-Percent-Sensitivity-for-Colorectal-Cancer-at-91-Percent-Specificity-Raising-the-Bar-in-Non-invasive-Screening/default.aspx

Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening

BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity

20,000-participant study reflects racial and ethnic diversity of the U.S.

Company plans to complete FDA submission for next-generation Cologuard by end of 2023

Not much difference in the two study results. MYNZ has very little cash though an will need to raise. But but an incredible difference in Market cap between it and EXAS and the results for MYNZ looked promising. MYNZ might be a good value and ought to be a buyout target.

[Fred Kadiddlehopper]

Interesting indeed. Does EXAS/Cologuard have any other US competitors currently or on the horizon?